Johnson & Johnson wins FDA priority review for drug delivery system
July 17, 2025
Johnson & Johnson (NYSE:JNJ) announced today that the FDA granted priority review to a new drug application (NDA) for its TAR-200.
Johnson & Johnson (NYSE:JNJ) announced today that the FDA granted priority review to a new drug application (NDA) for its TAR-200.
Artificial intelligence (AI) models trained on large datasets are increasingly seen as the key to unlocking personalized treatments for brain disorders. An important bottleneck for scaling AI is the cost of data collection. This raises a fundamental dilemma: is it more cost-effective to scan more people for a short time, or fewer people for longer?
With the help of artificial intelligence (AI), an inexpensive test found in many doctors’ offices may soon be used to screen for hidden heart disease.
As cancer cases have increased worldwide, the disease has become more complex, presenting challenges to scientific advances in diagnosis and treatment. In this context, artificial intelligence (AI) has emerged as a valuable tool for predicting and detecting cases.
Recently, researchers from Prof. Eran Segal’s laboratory at the Weizmann Institute of Science have harnessed artificial intelligence to create a personalized “digital twin” that allows them to detect a risk of developing diseases, initiate preventive treatment and even run simulations to predict which treatment will be most effective.
“Precision medicine” has become increasingly popular in the last decade as an avenue for cancer therapy, where treatment strategies are tailored to a specific patient based on the unique characteristics of their disease and their personal background.
Innovative software platform leverages artificial intelligence to personalize therapy decisions and improve clinical outcomes for prostate cancer patients.
AI-Powered 3D Surgical Planning Tool Advances Precision Breast Cancer Surgery with Latest Regulatory Milestone
The FDA has granted 510(k) clearance to the TaviPilot AI software developed by Caranx Medical, according to company officials.
An artificial intelligence (AI) model developed by Mayo Clinic and Ultromics, Ltd., an AI echocardiography company based in Oxford, England, is highly accurate in screening for cardiac amyloidosis, a rare and progressive type of heart failure, according to a new study. The model is the first and only AI tool of its kind.